Fibromyalgia is a disorder that causes enormous suffering. However, it is not life-threatening. For most patients the results are usually discouraging when using a single form of treatment in isolation. When phase two and phase three principles are utilized without first identifying and treating an underlying causative factor, results improve from direct symptomatic management. One study found that 47% of patients with Fibromyalgia no longer fulfilled ACR criteria two years after diagnosis and remission objectively occurred in 24.2%. When a phase one approach is also included, greater than 74% of patients will respond favorably. That mere fact that the pharmaceutical companies are now spending research and development monies on this disorder should provide increasing hope to the millions of Fibromyalgia sufferers that even better and more promising therapies are on the horizon.